Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination with Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD(Phase 2). This evidence concerns the gene VEGFA and fibrosis.